King B F, Townsend-Nicholson A, Burnstock G
Autonomic Neuroscience Institute, Royal Free Hospital School of Medicine, Hampstead, London, UK.
Trends Pharmacol Sci. 1998 Dec;19(12):506-14. doi: 10.1016/s0165-6147(98)01271-1.
In the past five years, an extended series (P2Y1-n) of metabotropic nucleotide (P2) receptors has been cloned from vertebrate tissues; these receptors are activated by either ATP or UTP, or both nucleotides. While certain cloned P2Y receptors appear to correspond functionally to particular native P2 receptor phenotypes, such pharmacological phenotypes could be explained by either a combination of several members of the P2Y1-n series being coexpressed in the same tissue or the existence of novel, uncloned P2Y subtypes. Here, Brian King, Andrea Townsend-Nicholson and Geoffrey Burnstock review recent findings on the matter of pharmacological relationships between native P2 and cloned P2Y receptors.
在过去五年中，已从脊椎动物组织中克隆出一系列（P2Y1-n）代谢型核苷酸（P2）受体；这些受体可被ATP或UTP，或两种核苷酸激活。虽然某些克隆的P2Y受体在功能上似乎与特定的天然P2受体表型相对应，但这种药理学表型可能是由P2Y1-n系列的几个成员在同一组织中共表达，或者存在新的、未克隆的P2Y亚型来解释的。在此，布莱恩·金、安德里亚·汤森-尼科尔森和杰弗里·伯恩斯托克回顾了关于天然P2和克隆的P2Y受体之间药理学关系这一问题的最新研究发现。
